Top Markets
Coin of the day
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.

VTGN
Helyezés a részvények között #31931
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Részvényárfolyam
$0.2619
Utolsó szinkronizálás: 2026-08-17
Piaci kapitalizáció
$11.62M
Változás (1 nap)
-2.13%
Változás (1 év)
-92.30%
Ország
US
Kereskedés VistaGen Therapeutics, Inc. (VTGN)

Kategória

VistaGen Therapeutics, Inc. (VTGN) P/B aránya
P/B arány ekkor: 2026 TTM: 0
VistaGen Therapeutics, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 0. 2026 végén ez az arány 0 volt.
P/B arány története a(z) VistaGen Therapeutics, Inc. esetén 2026 és 2026 között
P/B arány az év végén
Év P/B arány Változtassa meg
Nincs elég adat a megadott dátumokhoz.
P/B arány hasonló vállalatoknál vagy versenytársaknál
Vállalat P/B arány P/B arány különbség Ország
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR